Emotion recognition and monitoring based on commonly used wearable devices can play an important role in psychological health monitoring and human-computer interaction. However, the existing methods cannot rely on the common smart bracelets or watches for emotion monitoring in daily life. To address this issue, our study proposes a method for emotional recognition using heart rate data from a wearable smart bracelet. A ‘neutral + target’ pair emotion stimulation experimental paradigm was presented, and a dataset of heart rate from 25 subjects was established, where neutral plus target emotion (neutral, happy, and sad) stimulation video pairs from China’s standard Emotional Video Stimuli materials (CEVS) were applied to the recruited subjects. Normalized features from the data of target emotions normalized by the baseline data of neutral mood were adopted. Emotion recognition experiment results approved the effectiveness of ‘neutral + target’ video pair simulation experimental paradigm, the baseline setting using neutral mood data, and the normalized features, as well as the classifiers of Adaboost and GBDT on this dataset. This method will promote the development of wearable consumer electronic devices for monitoring human emotional moods.

Despite the widespread clinical application of chemotherapeutic anticancer drugs, their adverse side effects and inefficient performances remain ongoing issues. A drug delivery system (DDS) designed for a specific cancer may therefore overcome the drawbacks of single chemotherapeutic drugs and provide precise and synergistical cancer treatment by introducing exclusive stimulus responsiveness and combined chemotherapy properties. Herein, we report the design and synthesis of a supramolecular drug delivery assembly 1 constructed by orthogonal self-assembly technique in aqueous media specifically for application in liver cancer therapy. Complex 1 incorporates the β-cyclodextrin host molecule-functionalized organoplatinum(II) metallacycle 2 with two specific stimulus-responsive motifs to the signaling molecule nitric oxide (NO), in addition to the three-armed polyethylene glycol (PEG) functionalized ferrocene 3 with redox responsiveness. With this molecular design, the particularly low critical aggregation concentration (CAC) of assembly 1 allowed encapsulation of the commercial anticancer drug doxorubicin (DOX). Controlled drug release was also achieved by morphological transfer via a sensitive response to the endogenous redox and NO stimuli, which are specifically related to the microenvironment of liver tumor cells. Upon combination of these properties with the anticancer ability from the platinum acceptor, in vitro studies demonstrated that DOX-loaded 1 is able to codeliver anticancer drugs and exhibit therapeutic effectiveness to liver tumor sites via a synergistic effect, thereby revealing a potential DDS platform for precise liver cancer therapeutics.

No abstract

The dianthracene-based rhomboidal organoplatinum­(II) metallacycle 1 was successfully obtained via coordination-driven self-assembly involving the combination of diplatinum­(II) acceptor 2 and dipyridyl donor 3. A dilute acetone solution of the prepared metallacycle exhibited temperature-responsive fluorescence involving a gradual red-shifted fluorescent change from cyan to yellow over a wide temperature range from 77 to 297 K. Notably, a linear correlation was observed between the emission maximum and temperature in the low-temperature region from 77 to 137 K. Additionally, the supramolecular coordination complex in the solid state showed reversible mechanochromic fluorescence behavior with an obvious color change between green and yellow. Further investigation revealed that a morphology change before and after grinding was responsible for the observed mechanofluorochromic phenomenon. These studies provide new insight into the preparation of well-defined supramolecular organoplatinum­(II) metallacycles capble of responding to multiple stimuli.